Auxilium Pharmaceuticals raises $115.7 million for general corporate purposes

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) announced today that it has closed its previously announced public offering of 3,000,000 shares of its common stock at a price of $34.50 per share. On September 29, 2009, Jefferies & Company, acting as the sole book-running manager of the offering, exercised in full its over-allotment option to purchase an additional 450,000 shares of common stock. The exercise of the option increased the size of the offering to an aggregate of 3,450,000 shares of common stock.

Auxilium received proceeds, net of offering expenses and underwriting discounts and commissions, of approximately $115.7 million. Auxilium offered the shares of its common stock sold in the offering pursuant to a Registration Statement on Form S-3 (Reg. No. 333-133477) filed with the Securities and Exchange Commission on August 27, 2007 and declared effective on September 19, 2007.

Auxilium expects to use the net proceeds from the sale of the shares of its common stock sold in the offering for general corporate purposes, including working capital, product development and capital expenditures.

Source:

Auxilium Pharmaceuticals, Inc.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative approaches target PAR2 receptor to alleviate gut pain